Hospital finance leaders have beaten back 340B payment cuts, site-neutral reimbursement and Medicaid rollbacks before. They have never had to model all three landing in the same fiscal year.
That is the challenge in front of them now.
CMS’ proposed 2027 outpatient rule, released July 2, would cut billions from 340B drug payments and push site-neutral rates into imaging. Medicaid work requirements under HR 1 also take effect in 2027, when coverage losses are expected to accelerate. Large, for-profit health systems have already acknowledged underestimating the impact of the ACA enhanced premium tax credits’ expiration on their 2026 results. And the Health Resources and Services Administration’s revised 340B rebate pilot is set to go live Jan. 1, 2027.
Each policy carries its own advocacy campaign, legal uncertainty and chance of changing before implementation. But CFOs cannot build a 2027 budget around policy probabilities. What matters is the cumulative financial impact.
Three lines, one fiscal year
The outpatient rule carries two distinct 340B hits.
CMS proposes paying for 340B-acquired drugs at average sales price minus 33.4%, down from average sales price plus 6%, a change the agency estimates would cut Original Medicare drug payments by $4.55 billion in the first year.
Separately, the agency wants to raise the annual “remedy” offset to the outpatient conversion factor from 0.5% to 3%, completing recovery of $7.8 billion in prior overpayments by 2029 instead of stretching it across another decade. Hospital groups have opposed compressing this timeline, and this proposal would do exactly that.
Site-neutral payment would extend to imaging without contrast — including most X-rays and MRIs — provided in excepted off-campus provider-based departments. CMS puts the first-year reduction in Part B spending at about $260 million. Rural sole community hospitals would be exempt. Surgical services are the widely expected next target, following drug administration in the 2026 rule and imaging in this one.
On the coverage side, the Congressional Budget Office estimates HR 1 will cut federal Medicaid spending by $911 billion over 10 years and leave 10 million more people uninsured by 2034. The 2034 figure is the one that gets quoted. The 2027 figure is the one that belongs in the model: CBO projects 5.2 million more uninsured next year relative to its baseline, up from 1.3 million this year. Work requirements of 80 hours per month for expansion adults ages 19 to 64 begin in 2027, alongside more frequent eligibility redeterminations.
Restrictions on state-directed payments and provider taxes phase in later in the decade, which is why they tend to fall out of near-term modeling. They should not. CMS projects 39 state-directed payment programs will move more than $140 billion in 2026, and a pre-enactment analysis of 25 states found that capping those payments at Medicare rates would cut Medicaid hospital revenue by more than 20% in 19 of them, according to The Commonwealth Fund.
Where 340B dollars actually go
The 340B question is not a pharmacy budget question. It is a service line question.
Systems have used 340B margin to underwrite oncology infusion, behavioral health, community outreach pharmacy and rural clinics that do not cover their own costs. When the spread compresses, the loss does not show up in a pharmacy cost center. It shows up in whichever programs were being cross-subsidized, and those are rarely the programs a board wants to close.
Budget neutrality makes the distribution uneven in a way sector-level numbers hide. Because statute requires CMS to recycle the savings, the agency would raise payments for non-drug outpatient services by 8.44%. Hospitals with modest 340B exposure could finish ahead. Disproportionate share hospitals with heavy infusion volume could absorb a significant net cut while the sector reports a 1.9% overall payment increase.
That exposure is also eroding independently of the rule. Drugmakers have moved to restrict contract pharmacy arrangements and, in June, Eli Lilly began denying 340B pricing to hospitals that would not submit in-house pharmacy claims data. The broader 340B fight is now running on at least four tracks at once: the outpatient rule, the rebate pilot, manufacturer conditions and litigation.
The cushion is already gone
The convergence would be manageable against a strong balance sheet. Most hospitals and health systems do not have one.
National operating margins fell 5% year over year through the first five months of 2026, according to Kaufman Hall, with the West down 12%. A recent analysis from the Urban Institute and Robert Wood Johnson Foundation found that 39% of hospitals were already losing money before any of the federal changes took effect. Bad debt and charity care per calendar day rose 16% year over year in May.
The forecasts stack on top of that baseline. Premier estimates hospitals will lose $68.6 billion in revenue across 2026 and 2027 from rising uninsurance tied to Medicaid and marketplace changes. The Commonwealth Fund projects work requirements alone could cut operating margins by an average of 13.3% in expansion states and by as much as 29.6% at safety-net hospitals.
Hospitals are responding as the financial pressure builds. Becker’s is tracking 42 hospitals that have closed departments or ended services, along with a growing list of systems cutting jobs in 2026.
Comments on the outpatient proposal are due Aug. 31, with a final rule expected in late October or early November.
The rules may still change, but the direction of travel is clear: less coverage, tighter reimbursement and more pressure on hospital margins. Leaders that wait for final rules risk starting too late. The systems best positioned for 2027 are likely to be those modeling the combined impact now and deciding early where to preserve access, absorb losses or pull back.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
